Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Dirui Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - Dirui Medical's closing stock price is 13.61 yuan, with a PE ratio of 103.67, which is substantially higher than the industry average of 49.45 and the median of 35.92 [1][2] - The company has a total market capitalization of 3.711 billion yuan, ranking 106th in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, five institutions hold shares in Dirui Medical, with a total of 115.7415 million shares valued at 1.690 billion yuan [1] - The main business of Dirui Medical includes the research, production, marketing, and service of medical testing instruments and related reagents, with a total of 213 patents, including 136 invention patents [1] - The latest quarterly report shows that the company achieved an operating income of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, a year-on-year decrease of 87.13%, with a gross profit margin of 42.78% [1]

Core Viewpoint - The stock of Dirui Medical closed at 13.78 yuan, marking a 1.62% increase, with a rolling PE ratio of 104.96, the lowest in 39 days, and a total market capitalization of 3.758 billion yuan [1] Company Summary - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related test strips and reagents [1] - The company has a total of 213 patents, including 136 invention patents, and has obtained 96 software copyrights [1] - For Q1 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13%, with a gross profit margin of 42.78% [1] Industry Summary - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, placing Dirui Medical at 107th in the industry ranking [2] - The static PE ratio for Dirui Medical is 26.48, and the price-to-book ratio is 1.82 [2] - The total market capitalization of Dirui Medical is 3.758 billion yuan, compared to the industry average market capitalization of 10.836 billion yuan [2]

Group 1: Company Performance and Strategy - In Q1 2025, the company installed over 400 high-speed instruments in the domestic market, improving reagent sales ratio through optimized sales structure [2] - The company adjusted its international sales strategy, focusing on Southeast Asia and Belt and Road countries, with minimal impact from uncontrollable factors [2] - The management aims to enhance reagent sales, reduce costs, and improve operational efficiency in response to performance challenges [2] Group 2: Profit Distribution and Shareholder Returns - The profit distribution plan for 2024 involves a cash dividend of RMB 2.60 per 10 shares, based on a total share capital of 272,700,161 shares, implemented on May 20, 2025 [3] - The company emphasizes long-term development while balancing short-term profit distribution to enhance investor returns [3] Group 3: Cost Reduction and Efficiency Improvement - The company is implementing measures to reduce costs and improve efficiency, including strengthening internal management and optimizing financial controls [4] - Ongoing efforts are focused on enhancing risk management capabilities to ensure sustainable profitability [4] Group 4: Research and Development Investments - The company is committed to R&D innovation, launching competitive products like the CS-690 automatic urine biochemical analyzer and CM-640 automatic chemiluminescence immunoassay analyzer [5][6] - R&D efforts are aligned with market trends, particularly in smart medical technology, enhancing the company's innovation capabilities [5][6] Group 5: Future Performance Improvement Measures - The company will focus on increasing reagent sales, improving accounts receivable, cash flow, and inventory management, while implementing a four-dimensional management approach [7] - The management is dedicated to ensuring stable and healthy company development [7] Group 6: Market Trends and Challenges - The in vitro diagnostic industry is driven by aging populations, domestic substitution, and new medical infrastructure, presenting opportunities for market share growth [9] - The company has established competitive advantages through over 30 years of independent R&D and has expanded its products to over 120 countries [9] Group 7: Market Value Management - The company has established a market value management system linked to executive performance evaluations, recognizing the importance of market performance for shareholder value [8] - The company plans to regularly review and adjust its market value management strategies in response to market conditions [8]

Company Overview - Dirui Medical's closing price on May 26 was 13.33 yuan, down 1.48%, with a rolling PE ratio of 101.54 times and a total market value of 3.635 billion yuan [1] - The company ranks 107th in the medical device industry, which has an average PE ratio of 48.92 times and a median of 35.68 times [1][2] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, with key products including urine analysis, biochemical analysis, chemiluminescence immunoassay, gynecological secretion analysis, blood cell analysis, coagulation analysis, and overall laboratory solutions [1] Financial Performance - In the first quarter of 2025, Dirui Medical reported operating revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1] - Over the past five days, the company experienced a net outflow of main funds amounting to 677,700 yuan, totaling 5.8154 million yuan in outflows [1]

Core Viewpoint - The company, Dirui Medical, is experiencing significant financial challenges, with a high price-to-earnings (PE) ratio compared to its industry peers, indicating potential overvaluation in the current market [1][2]. Company Summary - Dirui Medical's stock closed at 13.3 yuan, down 1.12%, with a rolling PE ratio of 101.31 times and a total market capitalization of 3.627 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, marketing, and service of medical testing instruments and related reagents [1]. - Dirui Medical has a total of 213 patents, including 136 invention patents and 96 software copyrights [1]. Financial Performance - In the first quarter of 2025, Dirui Medical reported revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13% year-on-year, with a gross profit margin of 42.78% [1]. Industry Comparison - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Dirui Medical at the 107th position in the industry ranking [1][2]. - The company has seen a net inflow of 2.36 million yuan in principal funds on May 22, but has experienced an overall outflow of 5.21 million yuan over the past five days [1].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-023 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，迪瑞医疗科技股份有限公司（以下简称 "公司"）将参加由吉林省证券业协会、深圳市全景网络有限公司共同举办的 "2025 年吉林辖区上市公司投资者网上集体接待日活动"，现将有关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可以登陆"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 27 日（周二）15:00-16:30。 届时公司副总经理、财务总监张兴艳女士，董事、副总经理、董事会秘书安国柱 先生将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况等投资者关 心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 迪瑞医疗科技股份有限公司董事会 迪瑞医疗科技股份有限公司 关于参加 2025 年吉林辖区上市公司投资者 网上集体接待日活动的公告 2025 年 5 月 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-022 迪瑞医疗科技股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）分别于2025年03月27日、 2025年04月18日召开了第六届董事会第五次会议及2024年年度股东大会，审议通 过了《关于变更公司经营范围暨修改<公司章程>的议案》等事项。具体内容详见 公司于巨潮资讯网（www.cninfo.com.cn）上披露的《关于变更公司经营范围暨 修改<公司章程>的公告》等相关公告。 按照长春市市场监督管理局长春新区分局的相关要求并经其核准，公司已于 近日完成了经营范围变更相关的工商变更登记工作，并取得由长春市市场监督管 理局长春新区分局换发的《营业执照》。公司经营范围变更为：一般项目：技术 服务、技术开发、技术咨询、技术交流、技术转让、技术推广；第一类医疗器械 生产；基础化学原料制造（不含危险化学品等许可类化学品的制造）；专用设备 制造（不含许可类专业设备制造）；工程和技术研究和试验发展；化工产品生产 （不含许可类 ...

Core Viewpoint - The company, Dirui Medical, is experiencing significant declines in revenue and net profit, with a high PE ratio compared to the industry average, indicating potential overvaluation in the current market context [1][2]. Company Summary - Dirui Medical's closing stock price is 13.31 yuan, down 1.04%, with a rolling PE ratio of 101.38 times and a total market capitalization of 3.63 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, marketing, and service of medical testing instruments and related reagents [1]. - Dirui Medical has a total of 213 patents, including 136 invention patents and 96 software copyrights [1]. - The latest financial report for Q1 2025 shows revenue of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.68 million yuan, down 87.13%, with a gross profit margin of 42.78% [1]. Industry Summary - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, positioning Dirui Medical at the 106th rank within the industry [2]. - The total market capitalization of the industry averages 10.56 billion yuan, indicating a significant disparity in valuation among companies [2].

迪瑞医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-021 本次分派对象为：截止 2025 年 5 月 19 日下午深圳证券交易所收市后，在中 国证券登记结算有限责任公司深圳分公司（以下简称"中国结算深圳分公司"） 登记在册的本公司全体股东。 五、权益分派方法 迪瑞医疗科技股份有限公司（以下简称"公司"）2024 年年度权益分派方案 已获 2025 年 4 月 18 日召开的 2024 年年度股东大会审议通过，现将分红派息事 宜公告如下： 一、股东大会审议通过权益分派方案情况 司实施分配方案时股权登记日的可参与利润分配的股本为基数，向全体股东每 未分配利润结转下一年度。根据第六届董事会第五次会议决议日公司总股本 若在方案公布后至实施前公司享有利润分配权的股份总额由于股票回购注 销等原因发生变化的，将按照分配比例【每 10 股派发现金股利人民币 2.6 元（含 税）】不变的原则对现金分红总额进行调整，在方案实施公告中按公司实施分配 方案时股权登记日可参与利润分配的股数来计算最终 ...